221 related articles for article (PubMed ID: 31377472)
21. Formulation and evaluation of anticancer and antiangiogenesis efficiency of PLA-PEG nanoparticles loaded with galbanic acid in C26 colon carcinoma, in vitro and in vivo.
Afsharzadeh M; Abnous K; Yazdian-Robati R; Ataranzadeh A; Ramezani M; Hashemi M
J Cell Physiol; 2019 May; 234(5):6099-6107. PubMed ID: 30378118
[TBL] [Abstract][Full Text] [Related]
22. Synergistic anti-tumor effect of dual drug co-assembled nanoparticles based on ursolic acid and sorafenib.
Tong LW; Le JQ; Song XH; Li CL; Yu SJ; Lin YQ; Tu YF; Shao JW
Colloids Surf B Biointerfaces; 2024 Feb; 234():113724. PubMed ID: 38183870
[TBL] [Abstract][Full Text] [Related]
23. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
24. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
25. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.
Ke Y; Xiang C
Int J Nanomedicine; 2018; 13():8339-8354. PubMed ID: 30584304
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.
Da X; Cao B; Mo J; Xiang Y; Hu H; Qiu C; Zhang C; Lv B; Zhang H; He C; Yang Y
BMC Cancer; 2024 Feb; 24(1):273. PubMed ID: 38409035
[TBL] [Abstract][Full Text] [Related]
27. Mesenchymal Stem Cells Engineered to Secrete Pigment Epithelium-Derived Factor Inhibit Tumor Metastasis and the Formation of Malignant Ascites in a Murine Colorectal Peritoneal Carcinomatosis Model.
Yang L; Zhang Y; Cheng L; Yue D; Ma J; Zhao D; Hou X; Xiang R; Cheng P
Hum Gene Ther; 2016 Mar; 27(3):267-77. PubMed ID: 26756933
[TBL] [Abstract][Full Text] [Related]
28. Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action.
Bahman AA; Abaza MSI; Khoushiash SI; Al-Attiyah RJ
Int J Mol Med; 2018 Sep; 42(3):1695-1715. PubMed ID: 29901131
[TBL] [Abstract][Full Text] [Related]
29. Effects of surface modification of As
Song X; You J; Shao H; Yan C
Colloids Surf B Biointerfaces; 2018 Sep; 169():289-297. PubMed ID: 29793091
[TBL] [Abstract][Full Text] [Related]
30. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice.
Hase R; Miyamoto M; Uehara H; Kadoya M; Ebihara Y; Murakami Y; Takahashi R; Mega S; Li L; Shichinohe T; Kawarada Y; Kondo S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8737-44. PubMed ID: 16361561
[TBL] [Abstract][Full Text] [Related]
31. [Pigment epithelium-derived factor gene therapy inhibits the growth of transplanted human hepatocellular carcinoma in nude mice].
GAO Y; ZHANG W; ZHAO L; WANG XH
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):363-7. PubMed ID: 19497203
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two neurotrophic serpins reveals a small fragment with cell survival activity.
Winokur PN; Subramanian P; Bullock JL; Arocas V; Becerra SP
Mol Vis; 2017; 23():372-384. PubMed ID: 28706437
[TBL] [Abstract][Full Text] [Related]
33. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
34. Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer.
Wang Z; Zang A; Wei Y; An L; Hong D; Shi Y; Zhang J; Su S; Fang G
Drug Des Devel Ther; 2020; 14():1095-1105. PubMed ID: 32210538
[TBL] [Abstract][Full Text] [Related]
35. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of continuously administered PEDF-derived synthetic peptides against osteosarcoma growth and metastasis.
Broadhead ML; Choong PF; Dass CR
J Biomed Biotechnol; 2012; 2012():230298. PubMed ID: 22701300
[TBL] [Abstract][Full Text] [Related]
38. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma.
Matsumoto K; Ishikawa H; Nishimura D; Hamasaki K; Nakao K; Eguchi K
Hepatology; 2004 Jul; 40(1):252-9. PubMed ID: 15239109
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
Shukla SK; Kulkarni NS; Farrales P; Kanabar DD; Parvathaneni V; Kunda NK; Muth A; Gupta V
Pharm Res; 2020 Mar; 37(3):67. PubMed ID: 32166411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
